To advocate the value of genomics, biotech and medical
technologies as these new modalities enter and impact the
healthcare system and thereby improving patient outcomes,
improving quality and bringing value to the market place.
Members of the Institute include medical directors from
purchasers, plans and provider systems.
|
|